Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Nathan R. West, Katy Milne, ...
Supplementary Materials Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer Nathan R. West, Katy Milne, Pauline T. Truong, Nicol Macpherson, Brad H. Nelson, & Peter H. Watson
Figure S1. Expression of the 8-gene TIL signature in independent cohorts of estrogen receptor negative breast cancer. The Gene Expression Omnibus accession numbers for the four cohorts are as follows: (A) GSE6861 (the primary EORTC/neoadjuvant cohort assessed in this study, included here for comparison with the additional cohorts); (B) GSE21974; (C) GSE19615; (D) GSE18864. Box plots represent the average z-score values of the 8 TIL genes of patients from each clinical response category. For GSE21974, data derived from pre-treatment biopsies and post-treatment surgical specimens are indicated. For full cohort and methodological details, see the Materials and Methods section in the main manuscript.
Table S1. Clinical characteristics of the MBTB cohort, according to treatment received.
Tumor status
Lumpectomy (n=81)
Mastectomy (n=174)
Radiotherapy (n=100)
Anth. therapy (n=57)
CMF therapy (n=90)
No chemo (n=100)*
#
#
#
#
#
#
%
%
%
%
%
%
Age at diagnosis
5 cm unknown
11 64 2 4
14% 79% 2% 5%
22 36 97 19
13% 21% 56% 11%
9 74 11 6
9% 74% 11% 6%
4 32 9 12
7% 56% 16% 21%
11 64 9 6
12% 71% 10% 7%
17 60 19 4
17% 60% 19% 4%
Nodal status
negative positive unknown
31 34 16
38% 42% 20%
57 108 9
33% 62% 5%
36 58 6
36% 58% 6%
17 37 3
30% 65% 5%
30 58 2
33% 64% 2%
37 43 20
37% 43% 20%
Grade
1–2 3 unknown
39 35 7
48% 43% 9%
81 84 9
47% 48% 5%
50 44 6
50% 44% 6%
29 24 4
51% 42% 7%
37 45 7
41% 50% 8%
52 45 3
52% 45% 3%
ER†
negative positive
81 0
100% 0%
174 0
100% 0%
100 0
100% 0%
100 0
100% 0%
100 0
100% 0%
100 0
100% 0%
PR‡
negative positive unknown
66 15 0
81% 19% 0%
146 26 2
84% 15% 1%
77 23 0
77% 23% 0%
49 8 0
86% 14% 0%
74 16 0
82% 18% 0%
81 17 2
81% 17% 2%
Her2§
negative positive unknown
46 24 11
57% 30% 14%
111 34 29
64% 20% 17%
55 30 15
55% 30% 15%
41 10 6
72% 18% 11%
51 20 19
57% 22% 21%
60 27 13
60% 27% 13%
*8 patients received chemotherapy, but of an unknown regimen. These patients are not included in the systemic therapy columns. † ER negative status defined as
